ABIVAX DGAP-News: ABIVAX / Key word(s): Temporary Suspension Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis 2021-05-24 / 08:49 The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis PARIS, France, May 24, 2021 - 08:45 am (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces today the suspension of the trading of its shares until the publication of the results of its phase 2b study for the treatment of ulcerative colitis with ABX464. The Company expects to publish a press release on this topic today after market closure (May 24, 2021). About Abivax (www.abivax.com) Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_. Contacts Abivax Investors Press Relations & Investors Europe Communications LifeSci Advisors MC Services AG Regina Jehle Chris Maggos Anne Hennecke regina.jehle@abivax.com chris@lifesciadvisors.com anne.hennecke@mc-services.eu +33 6 24 50 69 63 +41 79 367 6254 +49 211 529 252 22 Public Relations France Public Relations France Public Relations USA Actifin DGM Conseil Rooney Partners LLC Ghislaine Gasparetto Thomas Roborel de Climens Marion Janic ggasparetto@actifin.fr thomasdeclimens@dgm-conseil.fr mjanic@rooneyco.com +33 6 21 10 49 24 +33 6 14 50 15 84 +1 212 223 4017 DISCLAIMER
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Special consideration should be given to the potential hurtles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and ethics committees of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC, clinical data, Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions. -----------------------------------------------------------------------------------------------------------------------
2021-05-24 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------
1199604 2021-05-24
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1199604&application_name=news(END) Dow Jones Newswires
May 24, 2021 02:50 ET (06:50 GMT)
